Use of natriuretic peptide measurement in the management of heart failure

Balion C, Don-Wauchope A, Hill S, Santaguida PL, Booth R, Brown JA, Oremus M, Ali U, Bustamam A, Sohel N, McKelvie R, Raina P
Record ID 32014000521
English
Authors' objectives: To assess the diagnostic accuracy of B-type natriuretic peptide (BNP) and N-terminalproBNP (NT-proBNP) for detecting heart failure (HF) To determine whether BNP and NT-proBNP are independent predictors of mortality andmorbidity in HF and whether they add to the predictive value of other markers To ascertain whether treatment guided by BNP or NT-proBNP improves outcomes in HFcompared with usual care To assess the biological variation of BNP and NT-proBNP in HF and non-HFpopulations
Authors' recommendations: BNP and NT-proBNP had good diagnostic performance for ruling out HF but were less accurate for ruling in HF. BNP and NT-proBNP had prognostic value in HF and the general population. Therapeutic value was inconclusive. Data on biological variation expressed the differences in results and individuality expected in patients, suggesting that serial measurements need to be interpreted carefully.
Details
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Humans
  • Natriuretic Peptides
  • Heart Failure
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.